

Evidence			
	Dabigatran (Pradaxa)	Apixaban (Eliquis)	Rivaroxaban (Xarelto)
Hemodialysis	Stangier, 2010 (human) YES Khadzhynov, 2013 (human) YES		
rFVIIa	Lambourne, 2012 (mice) NO Marlu, 2012 (human) YES Herrmann, 2014 (human) YES		Gruber, 2009 (baboon) YES Godier, 2012 (rabbit) NO Marlu, 2012 (human) NO Perzborn, 2013 (rat & baboon) YES Herrmann, 2014 (human) YES
3-factor PCC	Herrmann, 2014 (human) YES		Herrmann, 2014 (human) YES
4-factor PCC	Eerenberg, 2011 (human) NO Lambourne, 2012 (mice) NO Marlu, 2012 (human) NO Pragst, 2012 (rabbits) YES		Eerenberg, 2011 (human) YES Godier, 2012 (rabbit) NO Marlu, 2012 (human) NO Perzborn, 2013 (rat) YES
4-factor activated PCC	Khoo, 2012 (human) YES Lambourne, 2012 (mice) NO Marlu, 2012 (human) YES Herrmann, 2014 (human) YES		Gruber, 2009 (baboon) YES Marlu, 2012 (human) YES Perzborn, 2013 (rat & baboon) YES Herrmann, 2014 (human) YES

Options			
	Dabigatran (Pradaxa)	Apixaban (Eliquis)	Rivaroxaban (Xarelto)
Oral activated charcoal	Yes	Yes	Yes
Hemodialysis	Yes	No	No
Hemoperfusion with charcoal	Yes	No	No
FFP	No	No	No
rFVIIa	Unclear	Unclear	Unclear
3-factor PCC	Unclear	Unclear	Unclear
4-factor PCC	Unclear	Unclear	Possible
4-factor activated PCC	Possible	Unclear	Possible

References with Level of Evidence (LOE)

- Rivaroxaban insert*. Available from: <http://www.bayerresources.com.au/resources/uploads/PI/file9466.pdf>.
- Apixaban insert*. October 7, 2014]; Available from: http://packageinserts.bms.com/pi/pi_eliquis.pdf.
- Dabigatran insert*. October 7, 2014]; Available from: <http://bidocs.boehringeringelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf>.
- Facts and Comparisons*. October 12, 2014]; Available from: <http://www.factsandcomparisons.com/>.
- Aminocaproic acid insert*. October 12, 2014]; Available from: http://www.hospira.com/Images/EN-1485_81-5548_1.pdf.
- Tranexamic acid insert*. October 12, 2014]; Available from: <http://www.anzca.edu.au/communications/anzca-e-newsletter/enewsadvertisements/Product%20information%20-%20Pfizer.pdf>.
- Kcentra insert*. October 12, 2014]; Available from: <http://labeling.cslbehring.com/PI/US/Kcentra/EN/Kcentra-Prescribing-Information.pdf>.
- Bebulin insert*. October 12, 2014]; Available from: http://www.baxter.com/downloads/healthcare_professionals/products/bebulin_pi.pdf.
- Profilnine insert*. October 12, 2014]; Available from: <http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm261964.pdf>.
- FEIBA insert*. October 12, 2014]; Available from: http://www.feiba.com/us/forms/feiba_nf_pi.pdf.
- Barer, D., et al., *Cimetidine and tranexamic acid in the treatment of acute upper-gastrointestinal-tract bleeding*. N Engl J Med, 1983. 308(26): p. 1571-5. LOE II
- Bergqvist, D., S. Dahlgren, and Y. Hessman, *Local inhibition of the fibrinolytic system in patients with massive upper gastrointestinal hemorrhage*. Ups J Med Sci, 1980. 85(2): p. 173-8. LOE III
- Biggs, J.C., T.B. Hugh, and A.J. Dodds, *Tranexamic acid and upper gastrointestinal haemorrhage--a double-blind trial*. Gut, 1976. 17(9): p. 729-34. LOE II
- Brandt, M.T. and R.H. Haug, *Traumatic hyphema: a comprehensive review*. J Oral Maxillofac Surg, 2001. 59(12): p. 1462-70. LOE V
- Breckan, R.K., A.M. Wessel-Berg, and R. Jorde, *Non-*

- endoscopic first-line treatment of bleeding peptic ulcer with ranitidine and tranexamic acid. *Scand J Gastroenterol*, 2003. 38(9): p. 1000-1. LOE IV
16. Gutknecht, J.L. and Irthum, B. et al., [Evaluation of the treatment of aneurysmal meningeal hemorrhage with antifibrinolytic agents, calcium inhibitors and maintenance of effective blood volume]. *Agressologie*, 1990. 31(6): p. 340-3. LOE IV
 33. Henry, D.A. and D.L. O'Connell, *Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage*. *BMJ*, 1989. 298(6681): p. 1142-6. LOE II
 34. Herrmann, R., et al., *Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban*. *Thromb Haemost*, 2014. 111(5): p. 989-95. LOE IV
 35. Hillman, J., et al., *Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study*. *J Neurosurg*, 2002. 97(4): p. 771-8. LOE II
 36. Hollanders, D., J.M. Thomson, and P.F. Schofield, *Tranexamic acid therapy in ulcerative colitis*. *Postgrad Med J*, 1982. 58(676): p. 87-91. LOE II
 37. Htun, K.T., J. McFadyen, and H.A. Tran, *The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa*. *Ann Hematol*, 2014. 93(10): p. 1785-6. LOE V
 38. Kaatz, S., et al., *Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors*. *Am J Hematol*, 2012. 87 Suppl 1: p. S141-5. LOE V
 39. Khadzhyrov, D., et al., *Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease*. *Thromb Haemost*, 2013. 109(4): p. 596-605. LOE IV
 40. Khoo, T.L., et al., *The use of FEIBA(R) in the correction of coagulation abnormalities induced by dabigatran*. *Int J Lab Hematol*, 2013. 35(2): p. 222-4. LOE IV
 41. Lambourne, M.D., et al., *Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate*. *J Thromb Haemost*, 2012. 10(9): p. 1830-40. LOE IV
 42. Larsen, C.C., et al., *Considerable delay in diagnosis and acute management of subarachnoid haemorrhage*. *Dan Med Bull*, 2010. 57(4): p. A4139. LOE II
 43. Marlu, R., et al., *Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers*. *Thromb Haemost*, 2012. 108(2): p. 217-24. LOE II
 44. Maurice-Szamburski, A., T. Graillon, and N. Bruder, *Favorable outcome after a subdural hematoma treated with feiba in a 77-year-old patient treated by rivaroxaban*. *J Neurosurg Anesthesiol*, 2014. 26(2): p. 183. LOE V
 45. Neyens, R., et al., *Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG((R))) to guide decision-making*. *J Thromb Thrombolysis*, 2014. 37(2): p. 80-3. LOE V
 46. Perzborn, E., et al., *Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates*. *Thromb Haemost*, 2013. 110(1): p. 162-72. LOE IV
 47. Pollack CV, Reilly PA, Eikelboom JW, et al. *Idarucizumab for dabigatran reversal*. *NEJM*, 2015. 373: p. 511-20. LOE II
 48. Pragst, I., et al., *Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model*. *J Thromb Haemost*, 2012. 10(9): p. 1841-8. LOE IV
 49. Ross, B., et al., *Clinical experience of life-threatening dabigatran-related bleeding at a large, tertiary care, academic medical center: a case series*. *J Med Toxicol*, 2014. 10(2): p. 223-8. LOE IV
 50. Ross, J. and R. Al-Shahi Salman, *The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials*. *Curr Drug Saf*, 2012. 7(1): p. 44-54. LOE II
 51. Sabovic, M., J. Lavre, and B. Vujkovic, *Tranexamic acid is beneficial as adjunctive therapy in treating major upper gastrointestinal bleeding in dialysis patients*. *Nephrol Dial Transplant*, 2003. 18(7): p. 1388-91. LOE IV
 52. Samama, M.M. and C. Guinet, *Laboratory assessment of new anticoagulants*. *Clin Chem Lab Med*, 2011. 49(5): p. 761-72.
 53. Sankarankutty, A., et al., *TEG(R) and ROTEM(R) in trauma: similar test but different results? World J Emerg Surg*, 2012. 7 Suppl 1: p. S3. LOE V
 54. Scaglione, F., *New oral anticoagulants: comparative pharmacology with vitamin K antagonists*. *Clin Pharmacokinet*, 2013. 52(2): p. 69-82. LOE V
 55. Siegal, D.M., D.A. Garcia, and M.A. Crowther, *How I treat target-specific oral anticoagulant-associated bleeding*. *Blood*, 2014. 123(8): p. 1152-8. LOE V
 56. Siegal, D.M., et al., *Andexanet Alfa for the reversal of Xa inhibitor activity*. *NEJM*, 2015, 373(25):p 2413-24.
 57. Stangier, J., et al., *Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study*. *Clin Pharmacokinet*, 2010. 49(4): p. 259-68. LOE IV
 58. Starke, R.M., et al., *Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage*. *Stroke*, 2008. 39(9): p. 2617-21. LOE IV
 59. van Ryn, J., et al., *Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity*. *Thromb Haemost*, 2010. 103(6): p. 1116-27. LOE V
 60. von Holstein, C.C., S.B. Eriksson, and R. Kallen, *Tranexamic acid as an aid to reducing blood transfusion requirements in gastric and duodenal bleeding*. *Br Med J (Clin Res Ed)*, 1987. 294(6563): p. 7-10. LOE II
 61. Wanek, M.R., et al., *Safe use of hemodialysis for dabigatran removal before cardiac surgery*. *Ann Pharmacother*, 2012. 46(9): p. e21. LOE V
 62. Warkentin, T.E., et al., *Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding*. *Blood*, 2012. 119(9): p. 2172-4. LOE V
 63. Wong, H. and D. Keeling, *Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding*. *Br J Haematol*, 2014. 166(1): p. 152-3. LOE V
 64. Xu, Y., et al., *Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro*. *Blood Coagul Fibrinolysis*, 2013. 24(3): p. 332-8. LOE V
 65. Zhou, W., et al., *Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran*. *Stroke*, 2011. 42(12): p. 3594-9. LOE IV